These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 26202045)

  • 1. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
    Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
    Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
    Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
    Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
    Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
    Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
    Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
    Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
    Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.